Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1)

被引:0
|
作者
Swathi Lingam
Nopnithi Thonghin
Robert C. Ford
机构
[1] The University of Manchester,Faculty of Biology, Medicine and Health
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Ivacaftor is a potentiator of the CFTR chloride channel and is in worldwide clinical use for the chronic treatment of cystic fibrosis in patients. There is evidence that the bioavailability of ivacaftor in the body may be influenced by the multi-drug exporter P-glycoprotein. Here we have employed purified and reconstituted P-glycoprotein to study its interaction with ivacaftor as well as the ability of the drug to compete with a known transported substrate of the protein. We find that ivacaftor stimulates the ATPase activity of the purified protein and can compete with the transport of the fluorescent substrate Hoechst 33342. These findings lead us to conclude that ivacaftor is very likely an efficiently transported substrate of P-glycoprotein. Evidence for state-dependent binding of ivacaftor was obtained using a fluorescent, cysteine-reactive reporter dye. The quiescent, nucleotide-free state in the P-glycoprotein transport cycle appears to bind ivacaftor strongly.
引用
收藏
相关论文
共 50 条
  • [31] Genetic predictors of lamotrigine maintenance dose; A role for ABCB1 P-glycoprotein?
    Sills, Graeme J.
    Makmor-Bakry, M.
    Butler, E.
    Hitiris, N.
    Brodie, M. J.
    EPILEPSIA, 2007, 48 : 377 - 377
  • [32] Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia
    Maia, Raquel C.
    Vasconcelos, Flavia C.
    Souza, Paloma S.
    Rumjanek, Vivian M.
    MOLECULES, 2018, 23 (01):
  • [33] Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans
    Neil Macdonald
    Alex Gledhill
    Archives of Toxicology, 2007, 81 : 553 - 563
  • [34] Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide
    Pottier, Geraldine
    Marie, Solene
    Goutal, Sebastien
    Auvity, Sylvain
    Peyronneau, Marie-Anne
    Stute, Simon
    Boisgard, Raphael
    Dolle, Frederic
    Buvat, Irene
    Caille, Fabien
    Tournier, Nicolas
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (02) : 309 - 314
  • [35] Recent Advances on P-Glycoprotein (ABCB1) Transporter Modelling with In Silico Methods
    Mora Lagares, Liadys
    Novic, Marjana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [36] Functional Impact of ABCB1 Variants on Interactions between P-Glycoprotein and Methadone
    Hung, Chin-Chuan
    Chiou, Mu-Han
    Teng, Yu-Ning
    Hsieh, Yow-Wen
    Huang, Chieh-Liang
    Lane, Hsien-Yuan
    PLOS ONE, 2013, 8 (03):
  • [37] Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans
    Macdonald, Neil
    Gledhill, Alex
    ARCHIVES OF TOXICOLOGY, 2007, 81 (08) : 553 - 563
  • [38] Oral and inhaled corticosteroids: Differences in P-glycoprotein (ABCB1) mediated efflux
    Crowe, Andrew
    Tan, Ai May
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2012, 260 (03) : 294 - 302
  • [39] The mechanism of degradation of multidrug resistance-linked P-glycoprotein (ABCB1)
    Katayama, Kazuhiro
    Ambudkar, Suresh
    CANCER RESEARCH, 2009, 69
  • [40] Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)
    Hodges, Laura M.
    Markova, Svetlana M.
    Chinn, Leslie W.
    Gow, Jason M.
    Kroetz, Deanna L.
    Klein, Teri E.
    Altman, Russ B.
    PHARMACOGENETICS AND GENOMICS, 2011, 21 (03): : 152 - 161